NCT03697161View on ClinicalTrials.gov

A Study of OV101 in Individuals With Fragile X Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 17, 2018

Primary Completion Date

February 3, 2020

Study Completion Date

February 26, 2020

Conditions
Fragile X Syndrome (FXS)
Interventions
DRUG

OV101 (gaboxadol)

OV101 (gaboxadol)

Trial Locations (6)

21205

Ovid Therapeutics Investigative Site, Baltimore

37212

Ovid Therapeutics Investigative Site, Nashville

45229

Ovid Therapeutics Investigative Site, Cincinnati

60612

Ovid Therapeutics Investigative Site, Chicago

80045

Ovid Therapeutics Investigative Site, Aurora

95817

Ovid Therapeutics Investigative Site, Sacramento

Sponsors

Lead Sponsor

Healx AI
All Listed Sponsors
lead

Healx AI

INDUSTRY